ZyVersa Therapeutics Publish Paper In Angiogensis Peer-Review Journal That Demonstrated Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure And Function In Retinopathy Of Prematurity Animal Model
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics published a paper in the Angiogenesis peer-review journal demonstrating that their Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in an animal model of Retinopathy of Prematurity (ROP). The study showed that IC 100 suppressed retinal microglia activation, reduced retinal inflammation, and improved retinal function.
July 18, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ZyVersa Therapeutics' publication in Angiogenesis journal highlights the potential of their Inflammasome ASC Inhibitor IC 100 in treating Retinopathy of Prematurity, which could positively impact the company's stock price.
The publication in a reputable journal demonstrates the efficacy of ZyVersa's IC 100 in an animal model, which is a significant step towards potential clinical applications. This positive development is likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100